NASDAQ: CTNM
Contineum Therapeutics Inc Stock Ownership - Who owns Contineum Therapeutics?

Insider buying vs selling

Have Contineum Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Tim WatkinsCMO Head of Development2026-01-283,611$4.50
$16.25kBuy
Tim WatkinsCMO Head of Development2026-01-282,800$14.09
$39.44kSell
Tim WatkinsCMO Head of Development2026-01-28811$14.49
$11.75kSell
Daniel S. LorrainChief Scientific Officer2026-01-05500$11.13
$5.57kSell
Daniel S. LorrainChief Scientific Officer2026-01-053,670$10.35
$37.98kSell
Tim WatkinsCMO Head of Development2025-12-293,611$12.06
$43.56kSell
Tim WatkinsCMO Head of Development2025-12-293,611$4.50
$16.25kBuy
Daniel S. LorrainChief Scientific Officer2025-12-234,170$12.23
$51.01kSell

1 of 1

CTNM insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CTNM insiders and whales buy or sell their stock.

CTNM Shareholders

What type of owners hold Contineum Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP7.27%2,122,000$30.26MInstitution
Johnson Johnson6.78%1,979,173$28.22MInstitution
Johnson Johnson6.78%1,979,173$28.22MInsider
Suvretta Capital Management LLC5.89%1,720,000$24.53MInstitution
Franklin Resources Inc5.67%1,655,548$23.61MInstitution
Vanguard Group Inc3.30%964,232$13.75MInstitution
Balyasny Asset Management LP3.26%951,320$13.57MInstitution
Fmr LLC2.79%814,871$11.62MInstitution
Sectoral Asset Management Inc2.74%800,787$11.42MInstitution
Perceptive Advisors LLC2.45%714,592$10.19MInstitution

1 of 3

CTNM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CTNM59.89%9.23%Net SellingNet Selling
GLSI8.51%91.49%Net BuyingNet Buying
DMAC24.49%71.44%Net BuyingNet Buying
ALLO67.47%32.53%Net SellingNet Selling
BNTC68.38%8.49%Net BuyingNet Buying

Contineum Therapeutics Stock Ownership FAQ

Who owns Contineum Therapeutics?

Contineum Therapeutics (NASDAQ: CTNM) is owned by 59.89% institutional shareholders, 9.23% Contineum Therapeutics insiders, and 30.87% retail investors. Johnson Johnson is the largest individual Contineum Therapeutics shareholder, owning 1.98M shares representing 6.78% of the company. Johnson Johnson's Contineum Therapeutics shares are currently valued at $28.22M.

If you're new to stock investing, here's how to buy Contineum Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.